Company: BLLN
Filing Date: 2025-08-11
Form Type: DRS/A
Source: 0000950123-25-007483
Chunk: 133

Company: BillionToOne, Inc.
Filing Date: 2025-08-11
Form: DRS/A
Chunk 133
---
 of , representing year-over-year revenue growth
for the period. This translates to a net operating income improvement of approximately , from a net loss of for the six months ended June 30, 2024 to a net operating income of
for the six months ended June 30, 2025.

89

Since our founding, we have developed and commercially launched multiple products and achieved a number of significant
milestones as depicted in the chart below.

Key Corporate & Commercialization Milestones CORPORATE Company founded 2016 First shared lab space (half bench) 2017 2018 $15M Series A closed 2019 2020 PRENATAL NIH grant received for the first single-gene NIPT clinical study UNITY Fetal Risk Screen launched First single-gene NIPT validation study published in Nature Scientific Reports UNITY Aneuploidy Screen and Fetal RhD NIPT launched ACOG guidelines changed to recommend NIPT for all pregnant women $55M Series B closed 2021 First dedicated lab facility opened in Menlo Park (36,000 sqft) $125M Series C closed 2022 Lab facility expanded to Union City (+90,000 sqft) 2023 $130M Series D closed 500th employee hired 2024 2025 UNITY Fetal Antigen NIPT for alloimmunized pregnant patients launched Clinical outcomes data for UNITY Fetal Risk Screen published, demonstrating exceptional accuracy in general pregnancy population Global partnership with J&J Phase 3 clinical trial announced ACOG practice advisory changed, citing publications on UNITY Fetal RhD NIPT and Fetal Antigen NIPT 1,000,000th clinical test performed UNITY Fetal Risk Screen expanded to 14-gene conditions ONCOLOGY Northstar Select and Response launched for clinical use Northstar Select head-to-head study presented at ASCO Northstar Response's first clinical validation published Medicare coverage approved for Northstar Select Northstar Response V2 launched with 0.01% LOD ACOG: American College of Obstetricians and Gynecologists ASCO: American Society of Clinical Oncology AACR: American Association for Cancer Research

Our business model and key performance metrics

Our revenue is driven by selling and performing molecular diagnostic tests ordered by physicians and other providers. We generally bill the patients’ insurance
carrier, the patient, or a combination of both upon delivery of the test results. We first commercialized our prenatal products in 2019 and our oncology products in early 2023. Our revenue has grown